title: Assessment of the Price-Volume Agreement Program in South Korea.
abstract: The Price-Volume Agreement Program (PVAP) was promulgated in 2007 in South Korea as the first attempt to adjust drug pricing according to total consumption in order to contain drug expenditure. This study was designed to assess the impact of the PVAP on diabetes drug expenditure for a period of a 10-year period (2003-2012) using claims data from the National Health Insurance Service. We estimated a multilevel mixed-effects linear regression model by comparing the level of total monthly diabetes drug expenditure for drugs subject to PVAP and existing drugs after adjusting the average differences in drug expenditure before and after the PVAP. The monthly total expenditure for drugs that were newly listed through the PVAP (negotiation drugs) was 7.03% higher on average compared to that for existing drugs, controlling for the baseline differences in expenditure before and after the PVAP. This increase was observed in all four subgroups of diabetes drugs, including sitagliptin, vildagliptin, exenatide, and others. The growth rate of total diabetes drug expenditure was reduced after the PVAP despite the sustained escalation of expenditure levels, which may imply that the PVAP has the potential to be an effective tool for drug expenditure control in the long term.
authors: College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Republic of Korea.
authors: Euna
authors: E
authors: Han
authors: School of Pharmacy, Sungkyunkwan University, Republic of Korea.
authors: Sun-Young
authors: SY
authors: Park
authors: School of Pharmacy, Sungkyunkwan University, Republic of Korea. Electronic address: ekyung@skku.edu.
authors: Eui-Kyung
authors: EK
authors: Lee
mesh_terms: D003363:Cost Control / Q000379:methods / Q000706:statistics & numerical data*; D016527:Drug Costs / Q000706:statistics & numerical data*; D017850:Economics, Pharmaceutical; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000627:therapeutic use; D007345:Insurance Claim Review; D007349:Insurance, Health, Reimbursement / Q000191:economics; D015233:Models, Statistical; D009313:National Health Programs; D056910:Republic of Korea
chemical_list: D007004:Hypoglycemic Agents
keywords: Diabetes drugs; Drug expenditure; Fisher’s Ideal Index; Mixed-effects linear regression; Price–Volume Agreement Program